[Chronic pulmonary aspergillosis].
Aspergillus species causes a variety of pulmonary diseases, invasive pulmonary aspergillosis in severely immunocompromised patietnts, chronic pulmonary aspergillosis (CPA) in patients with chronic lung diseases and allergic bronchopulmonary aspergillosis in patients with hypersensitivity to Aspergillus antigens. There are many species of Aspergillus, however Aspergillus fumigatus is the most commonly encountered species. CPA is usually seen in patients with documented or suspected underlying lung diseases like cystic fibrosis, bronchiectasis, inactive tuberculosis, pulmonary fibrosis, sarcoidosis, previous lung section, of these, previous pulmonary tubercurosis is the most associated condition. Development of new antifungal agents, such as micafungin and voriconazole significantly affect the management and outcome of patients with CPA. This article reviews the clinical features, diagnosis, and treatment of CPA, and that provides recent advances in the CPA-related pathogenic factor.